<?xml version='1.0' encoding='UTF-8'?>
<uniprot xmlns="http://uniprot.org/uniprot" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://uniprot.org/uniprot http://www.uniprot.org/support/docs/uniprot.xsd">
<entry dataset="Swiss-Prot" created="1994-06-01" modified="2017-12-20" version="179">
<accession>P36888</accession>
<accession>A0AVG9</accession>
<accession>B7ZLT7</accession>
<accession>B7ZLT8</accession>
<accession>F5H0A0</accession>
<accession>Q13414</accession>
<name>FLT3_HUMAN</name>
<protein>
<recommendedName>
<fullName>Receptor-type tyrosine-protein kinase FLT3</fullName>
<ecNumber>2.7.10.1</ecNumber>
</recommendedName>
<alternativeName>
<fullName>FL cytokine receptor</fullName>
</alternativeName>
<alternativeName>
<fullName>Fetal liver kinase-2</fullName>
<shortName>FLK-2</shortName>
</alternativeName>
<alternativeName>
<fullName>Fms-like tyrosine kinase 3</fullName>
<shortName>FLT-3</shortName>
</alternativeName>
<alternativeName>
<fullName>Stem cell tyrosine kinase 1</fullName>
<shortName>STK-1</shortName>
</alternativeName>
<cdAntigenName>CD135</cdAntigenName>
</protein>
<gene>
<name type="primary">FLT3</name>
<name type="synonym">CD135</name>
<name type="synonym">FLK2</name>
<name type="synonym">STK1</name>
</gene>
<organism>
<name type="scientific">Homo sapiens</name>
<name type="common">Human</name>
<dbReference type="NCBI Taxonomy" id="9606"/>
<lineage>
<taxon>Eukaryota</taxon>
<taxon>Metazoa</taxon>
<taxon>Chordata</taxon>
<taxon>Craniata</taxon>
<taxon>Vertebrata</taxon>
<taxon>Euteleostomi</taxon>
<taxon>Mammalia</taxon>
<taxon>Eutheria</taxon>
<taxon>Euarchontoglires</taxon>
<taxon>Primates</taxon>
<taxon>Haplorrhini</taxon>
<taxon>Catarrhini</taxon>
<taxon>Hominidae</taxon>
<taxon>Homo</taxon>
</lineage>
</organism>
<reference key="1">
<citation type="journal article" date="1994" name="Proc. Natl. Acad. Sci. U.S.A." volume="91" first="459" last="463">
<title>STK-1, the human homolog of Flk-2/Flt-3, is selectively expressed in CD34+ human bone marrow cells and is involved in the proliferation of early progenitor/stem cells.</title>
<authorList>
<person name="Small D."/>
<person name="Levenstein M."/>
<person name="Kim E."/>
<person name="Carow C."/>
<person name="Amin S."/>
<person name="Rockwell P."/>
<person name="Witte L."/>
<person name="Burrow C."/>
<person name="Ratajczak M.Z."/>
<person name="Gewirtz A.M."/>
<person name="Civin C.I."/>
</authorList>
<dbReference type="PubMed" id="7507245"/>
<dbReference type="DOI" id="10.1073/pnas.91.2.459"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1)</scope>
<scope>FUNCTION</scope>
<scope>TISSUE SPECIFICITY</scope>
<source>
<tissue>Bone marrow</tissue>
</source>
</reference>
<reference key="2">
<citation type="journal article" date="1993" name="Blood" volume="82" first="1110" last="1119">
<title>Human FLT3/FLK2 gene: cDNA cloning and expression in hematopoietic cells.</title>
<authorList>
<person name="Rosnet O."/>
<person name="Schiff C."/>
<person name="Pebusque M.J."/>
<person name="Marchetto S."/>
<person name="Tonnelle C."/>
<person name="Toiron Y."/>
<person name="Birg F."/>
<person name="Birnbaum D."/>
</authorList>
<dbReference type="PubMed" id="8394751"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1)</scope>
<scope>TISSUE SPECIFICITY</scope>
<scope>VARIANT MET-227</scope>
<source>
<tissue>Lymphocyte</tissue>
</source>
</reference>
<reference key="3">
<citation type="journal article" date="2004" name="Nature" volume="428" first="522" last="528">
<title>The DNA sequence and analysis of human chromosome 13.</title>
<authorList>
<person name="Dunham A."/>
<person name="Matthews L.H."/>
<person name="Burton J."/>
<person name="Ashurst J.L."/>
<person name="Howe K.L."/>
<person name="Ashcroft K.J."/>
<person name="Beare D.M."/>
<person name="Burford D.C."/>
<person name="Hunt S.E."/>
<person name="Griffiths-Jones S."/>
<person name="Jones M.C."/>
<person name="Keenan S.J."/>
<person name="Oliver K."/>
<person name="Scott C.E."/>
<person name="Ainscough R."/>
<person name="Almeida J.P."/>
<person name="Ambrose K.D."/>
<person name="Andrews D.T."/>
<person name="Ashwell R.I.S."/>
<person name="Babbage A.K."/>
<person name="Bagguley C.L."/>
<person name="Bailey J."/>
<person name="Bannerjee R."/>
<person name="Barlow K.F."/>
<person name="Bates K."/>
<person name="Beasley H."/>
<person name="Bird C.P."/>
<person name="Bray-Allen S."/>
<person name="Brown A.J."/>
<person name="Brown J.Y."/>
<person name="Burrill W."/>
<person name="Carder C."/>
<person name="Carter N.P."/>
<person name="Chapman J.C."/>
<person name="Clamp M.E."/>
<person name="Clark S.Y."/>
<person name="Clarke G."/>
<person name="Clee C.M."/>
<person name="Clegg S.C."/>
<person name="Cobley V."/>
<person name="Collins J.E."/>
<person name="Corby N."/>
<person name="Coville G.J."/>
<person name="Deloukas P."/>
<person name="Dhami P."/>
<person name="Dunham I."/>
<person name="Dunn M."/>
<person name="Earthrowl M.E."/>
<person name="Ellington A.G."/>
<person name="Faulkner L."/>
<person name="Frankish A.G."/>
<person name="Frankland J."/>
<person name="French L."/>
<person name="Garner P."/>
<person name="Garnett J."/>
<person name="Gilbert J.G.R."/>
<person name="Gilson C.J."/>
<person name="Ghori J."/>
<person name="Grafham D.V."/>
<person name="Gribble S.M."/>
<person name="Griffiths C."/>
<person name="Hall R.E."/>
<person name="Hammond S."/>
<person name="Harley J.L."/>
<person name="Hart E.A."/>
<person name="Heath P.D."/>
<person name="Howden P.J."/>
<person name="Huckle E.J."/>
<person name="Hunt P.J."/>
<person name="Hunt A.R."/>
<person name="Johnson C."/>
<person name="Johnson D."/>
<person name="Kay M."/>
<person name="Kimberley A.M."/>
<person name="King A."/>
<person name="Laird G.K."/>
<person name="Langford C.J."/>
<person name="Lawlor S."/>
<person name="Leongamornlert D.A."/>
<person name="Lloyd D.M."/>
<person name="Lloyd C."/>
<person name="Loveland J.E."/>
<person name="Lovell J."/>
<person name="Martin S."/>
<person name="Mashreghi-Mohammadi M."/>
<person name="McLaren S.J."/>
<person name="McMurray A."/>
<person name="Milne S."/>
<person name="Moore M.J.F."/>
<person name="Nickerson T."/>
<person name="Palmer S.A."/>
<person name="Pearce A.V."/>
<person name="Peck A.I."/>
<person name="Pelan S."/>
<person name="Phillimore B."/>
<person name="Porter K.M."/>
<person name="Rice C.M."/>
<person name="Searle S."/>
<person name="Sehra H.K."/>
<person name="Shownkeen R."/>
<person name="Skuce C.D."/>
<person name="Smith M."/>
<person name="Steward C.A."/>
<person name="Sycamore N."/>
<person name="Tester J."/>
<person name="Thomas D.W."/>
<person name="Tracey A."/>
<person name="Tromans A."/>
<person name="Tubby B."/>
<person name="Wall M."/>
<person name="Wallis J.M."/>
<person name="West A.P."/>
<person name="Whitehead S.L."/>
<person name="Willey D.L."/>
<person name="Wilming L."/>
<person name="Wray P.W."/>
<person name="Wright M.W."/>
<person name="Young L."/>
<person name="Coulson A."/>
<person name="Durbin R.M."/>
<person name="Hubbard T."/>
<person name="Sulston J.E."/>
<person name="Beck S."/>
<person name="Bentley D.R."/>
<person name="Rogers J."/>
<person name="Ross M.T."/>
</authorList>
<dbReference type="PubMed" id="15057823"/>
<dbReference type="DOI" id="10.1038/nature02379"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]</scope>
</reference>
<reference key="4">
<citation type="submission" date="2005-07" db="EMBL/GenBank/DDBJ databases">
<authorList>
<person name="Mural R.J."/>
<person name="Istrail S."/>
<person name="Sutton G.G."/>
<person name="Florea L."/>
<person name="Halpern A.L."/>
<person name="Mobarry C.M."/>
<person name="Lippert R."/>
<person name="Walenz B."/>
<person name="Shatkay H."/>
<person name="Dew I."/>
<person name="Miller J.R."/>
<person name="Flanigan M.J."/>
<person name="Edwards N.J."/>
<person name="Bolanos R."/>
<person name="Fasulo D."/>
<person name="Halldorsson B.V."/>
<person name="Hannenhalli S."/>
<person name="Turner R."/>
<person name="Yooseph S."/>
<person name="Lu F."/>
<person name="Nusskern D.R."/>
<person name="Shue B.C."/>
<person name="Zheng X.H."/>
<person name="Zhong F."/>
<person name="Delcher A.L."/>
<person name="Huson D.H."/>
<person name="Kravitz S.A."/>
<person name="Mouchard L."/>
<person name="Reinert K."/>
<person name="Remington K.A."/>
<person name="Clark A.G."/>
<person name="Waterman M.S."/>
<person name="Eichler E.E."/>
<person name="Adams M.D."/>
<person name="Hunkapiller M.W."/>
<person name="Myers E.W."/>
<person name="Venter J.C."/>
</authorList>
</citation>
<scope>NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]</scope>
<scope>VARIANT MET-227</scope>
</reference>
<reference key="5">
<citation type="journal article" date="2004" name="Genome Res." volume="14" first="2121" last="2127">
<title>The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).</title>
<authorList>
<consortium name="The MGC Project Team"/>
</authorList>
<dbReference type="PubMed" id="15489334"/>
<dbReference type="DOI" id="10.1101/gr.2596504"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2)</scope>
<scope>VARIANT MET-227</scope>
</reference>
<reference key="6">
<citation type="journal article" date="1991" name="Genomics" volume="9" first="380" last="385">
<title>Isolation and chromosomal localization of a novel FMS-like tyrosine kinase gene.</title>
<authorList>
<person name="Rosnet O."/>
<person name="Mattei M.-G."/>
<person name="Marchetto S."/>
<person name="Birnbaum D."/>
</authorList>
<dbReference type="PubMed" id="2004790"/>
<dbReference type="DOI" id="10.1016/0888-7543(91)90270-O"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [MRNA] OF 783-942 (ISOFORM 1)</scope>
<source>
<tissue>Testis</tissue>
</source>
</reference>
<reference key="7">
<citation type="journal article" date="1996" name="Leukemia" volume="10" first="238" last="248">
<title>Human FLT3/FLK2 receptor tyrosine kinase is expressed at the surface of normal and malignant hematopoietic cells.</title>
<authorList>
<person name="Rosnet O."/>
<person name="Buhring H.J."/>
<person name="Marchetto S."/>
<person name="Rappold I."/>
<person name="Lavagna C."/>
<person name="Sainty D."/>
<person name="Arnoulet C."/>
<person name="Chabannon C."/>
<person name="Kanz L."/>
<person name="Hannum C."/>
<person name="Birnbaum D."/>
</authorList>
<dbReference type="PubMed" id="8637232"/>
</citation>
<scope>TISSUE SPECIFICITY</scope>
<scope>SUBCELLULAR LOCATION</scope>
</reference>
<reference key="8">
<citation type="journal article" date="1996" name="Leukemia" volume="10" first="1911" last="1918">
<title>Internal tandem duplication of the flt3 gene found in acute myeloid leukemia.</title>
<authorList>
<person name="Nakao M."/>
<person name="Yokota S."/>
<person name="Iwai T."/>
<person name="Kaneko H."/>
<person name="Horiike S."/>
<person name="Kashima K."/>
<person name="Sonoda Y."/>
<person name="Fujimoto T."/>
<person name="Misawa S."/>
</authorList>
<dbReference type="PubMed" id="8946930"/>
</citation>
<scope>INVOLVEMENT IN AML</scope>
</reference>
<reference key="9">
<citation type="journal article" date="1998" name="Leukemia" volume="12" first="1333" last="1337">
<title>Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product.</title>
<authorList>
<person name="Kiyoi H."/>
<person name="Towatari M."/>
<person name="Yokota S."/>
<person name="Hamaguchi M."/>
<person name="Ohno R."/>
<person name="Saito H."/>
<person name="Naoe T."/>
</authorList>
<dbReference type="PubMed" id="9737679"/>
<dbReference type="DOI" id="10.1038/sj.leu.2401130"/>
</citation>
<scope>INVOLVEMENT IN AML</scope>
<scope>SUBUNIT</scope>
<scope>PHOSPHORYLATION</scope>
<scope>MUTAGENESIS OF TYR-589 AND TYR-591</scope>
</reference>
<reference key="10">
<citation type="journal article" date="1999" name="J. Leukoc. Biol." volume="65" first="372" last="380">
<title>Flt3 signaling involves tyrosyl-phosphorylation of SHP-2 and SHIP and their association with Grb2 and Shc in Baf3/Flt3 cells.</title>
<authorList>
<person name="Zhang S."/>
<person name="Mantel C."/>
<person name="Broxmeyer H.E."/>
</authorList>
<dbReference type="PubMed" id="10080542"/>
</citation>
<scope>FUNCTION IN PROMOTING PHOSPHORYLATION OF SHC1; PTPN6/SHP; PTPN11/SHP-2; MAPK1/ERK2; MAPK3/ERK1</scope>
<scope>AUTOPHOSPHORYLATION</scope>
<scope>INTERACTION WITH GRB2</scope>
</reference>
<reference key="11">
<citation type="journal article" date="2000" name="Blood" volume="96" first="3907" last="3914">
<title>Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways.</title>
<authorList>
<person name="Mizuki M."/>
<person name="Fenski R."/>
<person name="Halfter H."/>
<person name="Matsumura I."/>
<person name="Schmidt R."/>
<person name="Muller C."/>
<person name="Gruning W."/>
<person name="Kratz-Albers K."/>
<person name="Serve S."/>
<person name="Steur C."/>
<person name="Buchner T."/>
<person name="Kienast J."/>
<person name="Kanakura Y."/>
<person name="Berdel W.E."/>
<person name="Serve H."/>
</authorList>
<dbReference type="PubMed" id="11090077"/>
</citation>
<scope>FUNCTION IN ACTIVATION OF AKT1; MAPK1/ERK2; MAPK3/ERK1; STAT5A AND STAT5B</scope>
<scope>PHOSPHORYLATION</scope>
<scope>FUNCTION IN ACTIVATION OF THE RAS PATHWAY</scope>
<scope>INVOLVEMENT IN AML</scope>
</reference>
<reference key="12">
<citation type="journal article" date="2005" name="Cancer Res." volume="65" first="9643" last="9650">
<title>Constitutive activation of Akt by Flt3 internal tandem duplications is necessary for increased survival, proliferation, and myeloid transformation.</title>
<authorList>
<person name="Brandts C.H."/>
<person name="Sargin B."/>
<person name="Rode M."/>
<person name="Biermann C."/>
<person name="Lindtner B."/>
<person name="Schwable J."/>
<person name="Buerger H."/>
<person name="Muller-Tidow C."/>
<person name="Choudhary C."/>
<person name="McMahon M."/>
<person name="Berdel W.E."/>
<person name="Serve H."/>
</authorList>
<dbReference type="PubMed" id="16266983"/>
<dbReference type="DOI" id="10.1158/0008-5472.CAN-05-0422"/>
</citation>
<scope>FUNCTION IN ACTIVATION OF AKT1</scope>
<scope>INVOLVEMENT IN AML</scope>
</reference>
<reference key="13">
<citation type="journal article" date="2005" name="Mol. Cell. Biol." volume="25" first="3690" last="3703">
<title>Tyrosine phosphorylation regulates maturation of receptor tyrosine kinases.</title>
<authorList>
<person name="Schmidt-Arras D.E."/>
<person name="Bohmer A."/>
<person name="Markova B."/>
<person name="Choudhary C."/>
<person name="Serve H."/>
<person name="Bohmer F.D."/>
</authorList>
<dbReference type="PubMed" id="15831474"/>
<dbReference type="DOI" id="10.1128/MCB.25.9.3690-3703.2005"/>
</citation>
<scope>SUBCELLULAR LOCATION</scope>
<scope>CATALYTIC ACTIVITY</scope>
<scope>PHOSPHORYLATION AT TYR-591</scope>
<scope>DEPHOSPHORYLATION BY PTPN1; PTPN6/SHP-1 AND PTPN12</scope>
<scope>PROTEASOMAL DEGRADATION</scope>
<scope>GLYCOSYLATION</scope>
<scope>MUTAGENESIS OF LYS-644</scope>
</reference>
<reference key="14">
<citation type="journal article" date="2006" name="Blood" volume="108" first="1339" last="1345">
<title>Roles of tyrosine 589 and 591 in STAT5 activation and transformation mediated by FLT3-ITD.</title>
<authorList>
<person name="Rocnik J.L."/>
<person name="Okabe R."/>
<person name="Yu J.C."/>
<person name="Lee B.H."/>
<person name="Giese N."/>
<person name="Schenkein D.P."/>
<person name="Gilliland D.G."/>
</authorList>
<dbReference type="PubMed" id="16627759"/>
<dbReference type="DOI" id="10.1182/blood-2005-11-011429"/>
</citation>
<scope>FUNCTION IN ACTIVATION OF STAT5A AND/OR STAT5B</scope>
<scope>PHOSPHORYLATION AT TYR-591; TYR-726; TYR-842; TYR-955 AND TYR-969</scope>
<scope>IDENTIFICATION BY MASS SPECTROMETRY</scope>
<scope>MUTAGENESIS OF TYR-589 AND TYR-591</scope>
</reference>
<reference key="15">
<citation type="journal article" date="2006" name="Blood" volume="108" first="1542" last="1550">
<title>Identification of Y589 and Y599 in the juxtamembrane domain of Flt3 as ligand-induced autophosphorylation sites involved in binding of Src family kinases and the protein tyrosine phosphatase SHP2.</title>
<authorList>
<person name="Heiss E."/>
<person name="Masson K."/>
<person name="Sundberg C."/>
<person name="Pedersen M."/>
<person name="Sun J."/>
<person name="Bengtsson S."/>
<person name="Ronnstrand L."/>
</authorList>
<dbReference type="PubMed" id="16684964"/>
<dbReference type="DOI" id="10.1182/blood-2005-07-008896"/>
</citation>
<scope>INTERACTION WITH PTPN11/SHP2; LYN; FGR; HCK AND SRC</scope>
<scope>AUTOPHOSPHORYLATION</scope>
<scope>MUTAGENESIS OF TYR-589 AND TYR-599</scope>
<scope>PHOSPHORYLATION AT TYR-572; SER-574; TYR-589; TYR-591 AND TYR-599</scope>
</reference>
<reference key="16">
<citation type="journal article" date="2008" name="Blood" volume="111" first="4930" last="4933">
<title>Structural and numerical variation of FLT3/ITD in pediatric AML.</title>
<authorList>
<person name="Meshinchi S."/>
<person name="Stirewalt D.L."/>
<person name="Alonzo T.A."/>
<person name="Boggon T.J."/>
<person name="Gerbing R.B."/>
<person name="Rocnik J.L."/>
<person name="Lange B.J."/>
<person name="Gilliland D.G."/>
<person name="Radich J.P."/>
</authorList>
<dbReference type="PubMed" id="18305215"/>
<dbReference type="DOI" id="10.1182/blood-2008-01-117770"/>
</citation>
<scope>REGION INVOLVED IN REGULATION OF KINASE ACTIVITY</scope>
<scope>AUTOREGULATORY DOMAIN</scope>
<scope>INVOLVEMENT IN AML</scope>
</reference>
<reference key="17">
<citation type="journal article" date="2008" name="J. Immunol." volume="180" first="7358" last="7367">
<title>Human Flt3 is expressed at the hematopoietic stem cell and the granulocyte/macrophage progenitor stages to maintain cell survival.</title>
<authorList>
<person name="Kikushige Y."/>
<person name="Yoshimoto G."/>
<person name="Miyamoto T."/>
<person name="Iino T."/>
<person name="Mori Y."/>
<person name="Iwasaki H."/>
<person name="Niiro H."/>
<person name="Takenaka K."/>
<person name="Nagafuji K."/>
<person name="Harada M."/>
<person name="Ishikawa F."/>
<person name="Akashi K."/>
</authorList>
<dbReference type="PubMed" id="18490735"/>
<dbReference type="DOI" id="10.4049/jimmunol.180.11.7358"/>
</citation>
<scope>FUNCTION</scope>
<scope>SUBCELLULAR LOCATION</scope>
<scope>TISSUE SPECIFICITY</scope>
</reference>
<reference key="18">
<citation type="journal article" date="2009" name="Exp. Hematol." volume="37" first="979" last="989">
<title>Oncogenic Flt3 receptors display different specificity and kinetics of autophosphorylation.</title>
<authorList>
<person name="Razumovskaya E."/>
<person name="Masson K."/>
<person name="Khan R."/>
<person name="Bengtsson S."/>
<person name="Ronnstrand L."/>
</authorList>
<dbReference type="PubMed" id="19477218"/>
<dbReference type="DOI" id="10.1016/j.exphem.2009.05.008"/>
</citation>
<scope>PHOSPHORYLATION AT TYR-589; TYR-591; TYR-599; TYR-726; TYR-768; TYR-793; TYR-842 AND TYR-955</scope>
</reference>
<reference key="19">
<citation type="journal article" date="2009" name="Mol. Cell. Proteomics" volume="8" first="1751" last="1764">
<title>Large-scale proteomics analysis of the human kinome.</title>
<authorList>
<person name="Oppermann F.S."/>
<person name="Gnad F."/>
<person name="Olsen J.V."/>
<person name="Hornberger R."/>
<person name="Greff Z."/>
<person name="Keri G."/>
<person name="Mann M."/>
<person name="Daub H."/>
</authorList>
<dbReference type="PubMed" id="19369195"/>
<dbReference type="DOI" id="10.1074/mcp.M800588-MCP200"/>
</citation>
<scope>PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-759 AND SER-993</scope>
<scope>IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]</scope>
</reference>
<reference key="20">
<citation type="journal article" date="2010" name="Leukemia" volume="24" first="721" last="728">
<title>FES kinases are required for oncogenic FLT3 signaling.</title>
<authorList>
<person name="Voisset E."/>
<person name="Lopez S."/>
<person name="Chaix A."/>
<person name="Georges C."/>
<person name="Hanssens K."/>
<person name="Prebet T."/>
<person name="Dubreuil P."/>
<person name="De Sepulveda P."/>
</authorList>
<dbReference type="PubMed" id="20111072"/>
<dbReference type="DOI" id="10.1038/leu.2009.301"/>
</citation>
<scope>FUNCTION IN ACTIVATION OF FES AND FER</scope>
<scope>INTERACTION WITH FES AND FER</scope>
</reference>
<reference key="21">
<citation type="journal article" date="2010" name="Leukemia" volume="24" first="1412" last="1421">
<title>Ubiquitin conjugase UBCH8 targets active FMS-like tyrosine kinase 3 for proteasomal degradation.</title>
<authorList>
<person name="Buchwald M."/>
<person name="Pietschmann K."/>
<person name="Muller J.P."/>
<person name="Bohmer F.D."/>
<person name="Heinzel T."/>
<person name="Kramer O.H."/>
</authorList>
<dbReference type="PubMed" id="20508617"/>
<dbReference type="DOI" id="10.1038/leu.2010.114"/>
</citation>
<scope>UBIQUITINATION</scope>
</reference>
<reference key="22">
<citation type="journal article" date="2010" name="Mol. Cancer" volume="9" first="292" last="292">
<title>mTOR signaling is activated by FLT3 kinase and promotes survival of FLT3-mutated acute myeloid leukemia cells.</title>
<authorList>
<person name="Chen W."/>
<person name="Drakos E."/>
<person name="Grammatikakis I."/>
<person name="Schlette E.J."/>
<person name="Li J."/>
<person name="Leventaki V."/>
<person name="Staikou-Drakopoulou E."/>
<person name="Patsouris E."/>
<person name="Panayiotidis P."/>
<person name="Medeiros L.J."/>
<person name="Rassidakis G.Z."/>
</authorList>
<dbReference type="PubMed" id="21067588"/>
<dbReference type="DOI" id="10.1186/1476-4598-9-292"/>
</citation>
<scope>FUNCTION</scope>
</reference>
<reference key="23">
<citation type="journal article" date="2011" name="J. Biol. Chem." volume="286" first="10918" last="10929">
<title>Protein-tyrosine phosphatase DEP-1 controls receptor tyrosine kinase FLT3 signaling.</title>
<authorList>
<person name="Arora D."/>
<person name="Stopp S."/>
<person name="Bohmer S.A."/>
<person name="Schons J."/>
<person name="Godfrey R."/>
<person name="Masson K."/>
<person name="Razumovskaya E."/>
<person name="Ronnstrand L."/>
<person name="Tanzer S."/>
<person name="Bauer R."/>
<person name="Bohmer F.D."/>
<person name="Muller J.P."/>
</authorList>
<dbReference type="PubMed" id="21262971"/>
<dbReference type="DOI" id="10.1074/jbc.M110.205021"/>
</citation>
<scope>INTERACTION WITH PTPRJ/DEP1</scope>
<scope>FUNCTION IN ACTIVATION OF MAPK1/ERK2; MAPK3/ERK1; PLCG1; STAT5A AND/OR STAT5B</scope>
<scope>GLYCOSYLATION</scope>
<scope>UBIQUITINATION</scope>
<scope>PHOSPHORYLATION AT TYR-572; TYR-589; TYR-591; TYR-599; TYR-768; TYR-793; TYR-842 AND TYR-955</scope>
</reference>
<reference key="24">
<citation type="journal article" date="2011" name="Oncogene" volume="30" first="4004" last="4014">
<title>Further activation of FLT3 mutants by FLT3 ligand.</title>
<authorList>
<person name="Zheng R."/>
<person name="Bailey E."/>
<person name="Nguyen B."/>
<person name="Yang X."/>
<person name="Piloto O."/>
<person name="Levis M."/>
<person name="Small D."/>
</authorList>
<dbReference type="PubMed" id="21516120"/>
<dbReference type="DOI" id="10.1038/onc.2011.110"/>
</citation>
<scope>FUNCTION</scope>
<scope>ENZYME REGULATION</scope>
</reference>
<reference key="25">
<citation type="journal article" date="2003" name="Nat. Rev. Cancer" volume="3" first="650" last="665">
<title>The role of FLT3 in haematopoietic malignancies.</title>
<authorList>
<person name="Stirewalt D.L."/>
<person name="Radich J.P."/>
</authorList>
<dbReference type="PubMed" id="12951584"/>
<dbReference type="DOI" id="10.1038/nrc1169"/>
</citation>
<scope>REVIEW</scope>
</reference>
<reference key="26">
<citation type="journal article" date="2009" name="Clin. Cancer Res." volume="15" first="4263" last="4269">
<title>Structural and functional alterations of FLT3 in acute myeloid leukemia.</title>
<authorList>
<person name="Meshinchi S."/>
<person name="Appelbaum F.R."/>
</authorList>
<dbReference type="PubMed" id="19549778"/>
<dbReference type="DOI" id="10.1158/1078-0432.CCR-08-1123"/>
</citation>
<scope>REVIEW</scope>
</reference>
<reference key="27">
<citation type="journal article" date="2004" name="Mol. Cell" volume="13" first="169" last="178">
<title>The structural basis for autoinhibition of FLT3 by the juxtamembrane domain.</title>
<authorList>
<person name="Griffith J."/>
<person name="Black J."/>
<person name="Faerman C."/>
<person name="Swenson L."/>
<person name="Wynn M."/>
<person name="Lu F."/>
<person name="Lippke J."/>
<person name="Saxena K."/>
</authorList>
<dbReference type="PubMed" id="14759363"/>
<dbReference type="DOI" id="10.1016/S1097-2765(03)00505-7"/>
</citation>
<scope>X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 564-958</scope>
<scope>ENZYME REGULATION</scope>
</reference>
<reference key="28">
<citation type="journal article" date="2011" name="Blood" volume="118" first="60" last="68">
<title>Structural insights into the extracellular assembly of the hematopoietic Flt3 signaling complex.</title>
<authorList>
<person name="Verstraete K."/>
<person name="Vandriessche G."/>
<person name="Januar M."/>
<person name="Elegheert J."/>
<person name="Shkumatov A.V."/>
<person name="Desfosses A."/>
<person name="Van Craenenbroeck K."/>
<person name="Svergun D.I."/>
<person name="Gutsche I."/>
<person name="Vergauwen B."/>
<person name="Savvides S.N."/>
</authorList>
<dbReference type="PubMed" id="21389326"/>
<dbReference type="DOI" id="10.1182/blood-2011-01-329532"/>
</citation>
<scope>X-RAY CRYSTALLOGRAPHY (4.3 ANGSTROMS) OF 27-436 IN COMPLEX WITH FLT3LG</scope>
<scope>SUBUNIT</scope>
<scope>INTERACTION WITH FLT3LG</scope>
<scope>GLYCOSYLATION AT ASN-43; ASN-100; ASN-151; ASN-306; ASN-323; ASN-351 AND ASN-354</scope>
<scope>IDENTIFICATION BY MASS SPECTROMETRY</scope>
<scope>DISULFIDE BONDS</scope>
</reference>
<reference key="29">
<citation type="journal article" date="2001" name="Br. J. Haematol." volume="113" first="983" last="988">
<title>Identification of novel FLT-3 Asp835 mutations in adult acute myeloid leukaemia.</title>
<authorList>
<person name="Abu-Duhier F.M."/>
<person name="Goodeve A.C."/>
<person name="Wilson G.A."/>
<person name="Care R.S."/>
<person name="Peake I.R."/>
<person name="Reilly J.T."/>
</authorList>
<dbReference type="PubMed" id="11442493"/>
<dbReference type="DOI" id="10.1046/j.1365-2141.2001.02850.x"/>
</citation>
<scope>VARIANTS TYR-835 DEL; HIS-835 AND TYR-835</scope>
<scope>INVOLVEMENT IN AML</scope>
</reference>
<reference key="30">
<citation type="journal article" date="2001" name="Blood" volume="97" first="2434" last="2439">
<title>Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies.</title>
<authorList>
<person name="Yamamoto Y."/>
<person name="Kiyoi H."/>
<person name="Nakano Y."/>
<person name="Suzuki R."/>
<person name="Kodera Y."/>
<person name="Miyawaki S."/>
<person name="Asou N."/>
<person name="Kuriyama K."/>
<person name="Yagasaki F."/>
<person name="Shimazaki C."/>
<person name="Akiyama H."/>
<person name="Saito K."/>
<person name="Nishimura M."/>
<person name="Motoji T."/>
<person name="Shinagawa K."/>
<person name="Takeshita A."/>
<person name="Saito H."/>
<person name="Ueda R."/>
<person name="Ohno R."/>
<person name="Naoe T."/>
</authorList>
<dbReference type="PubMed" id="11290608"/>
<dbReference type="DOI" id="10.1182/blood.V97.8.2434"/>
</citation>
<scope>VARIANTS ASN-835; GLU-835; HIS-835; VAL-835 AND TYR-835</scope>
<scope>CHARACTERIZATION OF VARIANTS ASN-835; GLU-835; HIS-835; VAL-835 AND TYR-835</scope>
<scope>PHOSPHORYLATION</scope>
<scope>INVOLVEMENT IN AML</scope>
</reference>
<reference key="31">
<citation type="journal article" date="2004" name="Blood" volume="103" first="1085" last="1088">
<title>FLT3 mutations in the activation loop of tyrosine kinase domain are frequently found in infant ALL with MLL rearrangements and pediatric ALL with hyperdiploidy.</title>
<authorList>
<person name="Taketani T."/>
<person name="Taki T."/>
<person name="Sugita K."/>
<person name="Furuichi Y."/>
<person name="Ishii E."/>
<person name="Hanada R."/>
<person name="Tsuchida M."/>
<person name="Sugita K."/>
<person name="Ida K."/>
<person name="Hayashi Y."/>
</authorList>
<dbReference type="PubMed" id="14504097"/>
<dbReference type="DOI" id="10.1182/blood-2003-02-0418"/>
</citation>
<scope>VARIANTS GLU-835; HIS-835; TYR-835; ILE-836 DEL AND MET-836</scope>
<scope>FUNCTION IN ACTIVATION OF STAT5A AND/OR STAT5B</scope>
<scope>PHOSPHORYLATION</scope>
<scope>INVOLVEMENT IN AML</scope>
</reference>
<reference key="32">
<citation type="journal article" date="2007" name="Nature" volume="446" first="153" last="158">
<title>Patterns of somatic mutation in human cancer genomes.</title>
<authorList>
<person name="Greenman C."/>
<person name="Stephens P."/>
<person name="Smith R."/>
<person name="Dalgliesh G.L."/>
<person name="Hunter C."/>
<person name="Bignell G."/>
<person name="Davies H."/>
<person name="Teague J."/>
<person name="Butler A."/>
<person name="Stevens C."/>
<person name="Edkins S."/>
<person name="O'Meara S."/>
<person name="Vastrik I."/>
<person name="Schmidt E.E."/>
<person name="Avis T."/>
<person name="Barthorpe S."/>
<person name="Bhamra G."/>
<person name="Buck G."/>
<person name="Choudhury B."/>
<person name="Clements J."/>
<person name="Cole J."/>
<person name="Dicks E."/>
<person name="Forbes S."/>
<person name="Gray K."/>
<person name="Halliday K."/>
<person name="Harrison R."/>
<person name="Hills K."/>
<person name="Hinton J."/>
<person name="Jenkinson A."/>
<person name="Jones D."/>
<person name="Menzies A."/>
<person name="Mironenko T."/>
<person name="Perry J."/>
<person name="Raine K."/>
<person name="Richardson D."/>
<person name="Shepherd R."/>
<person name="Small A."/>
<person name="Tofts C."/>
<person name="Varian J."/>
<person name="Webb T."/>
<person name="West S."/>
<person name="Widaa S."/>
<person name="Yates A."/>
<person name="Cahill D.P."/>
<person name="Louis D.N."/>
<person name="Goldstraw P."/>
<person name="Nicholson A.G."/>
<person name="Brasseur F."/>
<person name="Looijenga L."/>
<person name="Weber B.L."/>
<person name="Chiew Y.-E."/>
<person name="DeFazio A."/>
<person name="Greaves M.F."/>
<person name="Green A.R."/>
<person name="Campbell P."/>
<person name="Birney E."/>
<person name="Easton D.F."/>
<person name="Chenevix-Trench G."/>
<person name="Tan M.-H."/>
<person name="Khoo S.K."/>
<person name="Teh B.T."/>
<person name="Yuen S.T."/>
<person name="Leung S.Y."/>
<person name="Wooster R."/>
<person name="Futreal P.A."/>
<person name="Stratton M.R."/>
</authorList>
<dbReference type="PubMed" id="17344846"/>
<dbReference type="DOI" id="10.1038/nature05610"/>
</citation>
<scope>VARIANTS [LARGE SCALE ANALYSIS] ALA-158; MET-227; ASN-324; VAL-358 AND ILE-557</scope>
</reference>
<reference key="33">
<citation type="journal article" date="2008" name="Nature" volume="456" first="66" last="72">
<title>DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome.</title>
<authorList>
<person name="Ley T.J."/>
<person name="Mardis E.R."/>
<person name="Ding L."/>
<person name="Fulton B."/>
<person name="McLellan M.D."/>
<person name="Chen K."/>
<person name="Dooling D."/>
<person name="Dunford-Shore B.H."/>
<person name="McGrath S."/>
<person name="Hickenbotham M."/>
<person name="Cook L."/>
<person name="Abbott R."/>
<person name="Larson D.E."/>
<person name="Koboldt D.C."/>
<person name="Pohl C."/>
<person name="Smith S."/>
<person name="Hawkins A."/>
<person name="Abbott S."/>
<person name="Locke D."/>
<person name="Hillier L.W."/>
<person name="Miner T."/>
<person name="Fulton L."/>
<person name="Magrini V."/>
<person name="Wylie T."/>
<person name="Glasscock J."/>
<person name="Conyers J."/>
<person name="Sander N."/>
<person name="Shi X."/>
<person name="Osborne J.R."/>
<person name="Minx P."/>
<person name="Gordon D."/>
<person name="Chinwalla A."/>
<person name="Zhao Y."/>
<person name="Ries R.E."/>
<person name="Payton J.E."/>
<person name="Westervelt P."/>
<person name="Tomasson M.H."/>
<person name="Watson M."/>
<person name="Baty J."/>
<person name="Ivanovich J."/>
<person name="Heath S."/>
<person name="Shannon W.D."/>
<person name="Nagarajan R."/>
<person name="Walter M.J."/>
<person name="Link D.C."/>
<person name="Graubert T.A."/>
<person name="DiPersio J.F."/>
<person name="Wilson R.K."/>
</authorList>
<dbReference type="PubMed" id="18987736"/>
<dbReference type="DOI" id="10.1038/nature07485"/>
</citation>
<scope>VARIANT [LARGE SCALE ANALYSIS] MET-194</scope>
</reference>
<comment type="function">
<text evidence="8 9 12 16 17 21 24 26 27 29 30">Tyrosine-protein kinase that acts as cell-surface receptor for the cytokine FLT3LG and regulates differentiation, proliferation and survival of hematopoietic progenitor cells and of dendritic cells. Promotes phosphorylation of SHC1 and AKT1, and activation of the downstream effector MTOR. Promotes activation of RAS signaling and phosphorylation of downstream kinases, including MAPK1/ERK2 and/or MAPK3/ERK1. Promotes phosphorylation of FES, FER, PTPN6/SHP, PTPN11/SHP-2, PLCG1, and STAT5A and/or STAT5B. Activation of wild-type FLT3 causes only marginal activation of STAT5A or STAT5B. Mutations that cause constitutive kinase activity promote cell proliferation and resistance to apoptosis via the activation of multiple signaling pathways.</text>
</comment>
<comment type="catalytic activity">
<text evidence="7 15">ATP + a [protein]-L-tyrosine = ADP + a [protein]-L-tyrosine phosphate.</text>
</comment>
<comment type="enzyme regulation">
<text evidence="13 29">Present in an inactive conformation in the absence of bound ligand. FLT3LG binding leads to dimerization and activation by autophosphorylation.</text>
</comment>
<comment type="subunit">
<text evidence="3 8 18 24 27 28 34">Monomer in the absence of bound FLT3LG. Homodimer in the presence of bound FLT3LG. Interacts with FIZ1 following ligand activation (By similarity). Interacts with FES, FER, LYN, FGR, HCK, SRC and GRB2. Interacts with PTPRJ/DEP-1 and PTPN11/SHP2. Interacts with RNF115 and RNF126 (By similarity).</text>
</comment>
<comment type="interaction">
<interactant intactId="EBI-3946257"/>
<interactant intactId="EBI-81279">
<id>Q9Y6K9</id>
<label>IKBKG</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>2</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-3946257"/>
<interactant intactId="EBI-79464">
<id>P27986</id>
<label>PIK3R1</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>2</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-3946257"/>
<interactant intactId="EBI-2264500">
<id>Q12913</id>
<label>PTPRJ</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>3</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-3946257"/>
<interactant intactId="EBI-78302">
<id>P43405</id>
<label>SYK</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>21</experiments>
</comment>
<comment type="subcellular location">
<subcellularLocation>
<location>Membrane</location>
<topology>Single-pass type I membrane protein</topology>
</subcellularLocation>
<subcellularLocation>
<location>Endoplasmic reticulum lumen</location>
</subcellularLocation>
<text>Constitutively activated mutant forms with internal tandem duplications are less efficiently transported to the cell surface and a significant proportion is retained in an immature form in the endoplasmic reticulum lumen. The activated kinase is rapidly targeted for degradation.</text>
</comment>
<comment type="alternative products">
<event type="alternative splicing"/>
<isoform>
<id>P36888-1</id>
<name>1</name>
<sequence type="displayed"/>
</isoform>
<isoform>
<id>P36888-2</id>
<name>2</name>
<sequence type="described" ref="VSP_041796"/>
</isoform>
</comment>
<comment type="tissue specificity">
<text evidence="21 30 31 32">Detected in bone marrow, in hematopoietic stem cells, in myeloid progenitor cells and in granulocyte/macrophage progenitor cells (at protein level). Detected in bone marrow, liver, thymus, spleen and lymph node, and at low levels in kidney and pancreas. Highly expressed in T-cell leukemia.</text>
</comment>
<comment type="domain">
<text>The juxtamembrane autoregulatory region is important for normal regulation of the kinase activity and for maintaining the kinase in an inactive state in the absence of bound ligand. Upon tyrosine phosphorylation, it mediates interaction with the SH2 domains of numerous signaling partners. In-frame internal tandem duplications (ITDs) result in constitutive activation of the kinase. The activity of the mutant kinase can be stimulated further by FLT3LG binding.</text>
</comment>
<comment type="PTM">
<text evidence="15 27 28">N-glycosylated, contains complex N-glycans with sialic acid.</text>
</comment>
<comment type="PTM">
<text>Autophosphorylated on several tyrosine residues in response to FLT3LG binding. FLT3LG binding also increases phosphorylation of mutant kinases that are constitutively activated. Dephosphorylated by PTPRJ/DEP-1, PTPN1, PTPN6/SHP-1, and to a lesser degree by PTPN12. Dephosphorylation is important for export from the endoplasmic reticulum and location at the cell membrane.</text>
</comment>
<comment type="PTM">
<text evidence="25 27">Rapidly ubiquitinated by UBE2L6 and the E3 ubiquitin-protein ligase SIAH1 after autophosphorylation, leading to its proteasomal degradation.</text>
</comment>
<comment type="disease" evidence="9 10 11 12 16 20 33 34">
<disease id="DI-01171">
<name>Leukemia, acute myelogenous</name>
<acronym>AML</acronym>
<description>A subtype of acute leukemia, a cancer of the white blood cells. AML is a malignant disease of bone marrow characterized by maturational arrest of hematopoietic precursors at an early stage of development. Clonal expansion of myeloid blasts occurs in bone marrow, blood, and other tissue. Myelogenous leukemias develop from changes in cells that normally produce neutrophils, basophils, eosinophils and monocytes.</description>
<dbReference type="MIM" id="601626"/>
</disease>
<text>The gene represented in this entry may be involved in disease pathogenesis. Somatic mutations that lead to constitutive activation of FLT3 are frequent in AML patients. These mutations fall into two classes, the most common being in-frame internal tandem duplications of variable length in the juxtamembrane region that disrupt the normal regulation of the kinase activity. Likewise, point mutations in the activation loop of the kinase domain can result in a constitutively activated kinase.</text>
</comment>
<comment type="miscellaneous">
<text>Can be used as diagnostic tool to establish the exact cause of acute myeloid leukemia, and to determine the optimal therapy.</text>
</comment>
<comment type="similarity">
<text evidence="6">Belongs to the protein kinase superfamily. Tyr protein kinase family. CSF-1/PDGF receptor subfamily.</text>
</comment>
<comment type="online information" name="Atlas of Genetics and Cytogenetics in Oncology and Haematology">
<link uri="http://atlasgeneticsoncology.org/Genes/FLT3ID144.html"/>
</comment>
<dbReference type="EC" id="2.7.10.1"/>
<dbReference type="EMBL" id="U02687">
<property type="protein sequence ID" value="AAA18947.1"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="Z26652">
<property type="protein sequence ID" value="CAA81393.1"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="AL356915">
<property type="status" value="NOT_ANNOTATED_CDS"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="EMBL" id="AL445262">
<property type="status" value="NOT_ANNOTATED_CDS"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="EMBL" id="AL591024">
<property type="status" value="NOT_ANNOTATED_CDS"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="EMBL" id="CH471075">
<property type="protein sequence ID" value="EAX08424.1"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="EMBL" id="BC126350">
<property type="protein sequence ID" value="AAI26351.1"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="BC144039">
<property type="protein sequence ID" value="AAI44040.1"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="BC144040">
<property type="protein sequence ID" value="AAI44041.1"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="L36162">
<property type="protein sequence ID" value="AAA35487.1"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="CCDS" id="CCDS31953.1">
<molecule id="P36888-1"/>
</dbReference>
<dbReference type="PIR" id="A36873">
<property type="entry name" value="A36873"/>
</dbReference>
<dbReference type="PIR" id="A39061">
<property type="entry name" value="A39061"/>
</dbReference>
<dbReference type="RefSeq" id="NP_004110.2">
<molecule id="P36888-1"/>
<property type="nucleotide sequence ID" value="NM_004119.2"/>
</dbReference>
<dbReference type="UniGene" id="Hs.507590"/>
<dbReference type="PDB" id="1RJB">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.10"/>
<property type="chains" value="A=564-958"/>
</dbReference>
<dbReference type="PDB" id="3QS7">
<property type="method" value="X-ray"/>
<property type="resolution" value="4.30"/>
<property type="chains" value="E/F/G/H=27-436"/>
</dbReference>
<dbReference type="PDB" id="3QS9">
<property type="method" value="X-ray"/>
<property type="resolution" value="7.80"/>
<property type="chains" value="E/F/G/H=27-540"/>
</dbReference>
<dbReference type="PDB" id="4RT7">
<property type="method" value="X-ray"/>
<property type="resolution" value="3.10"/>
<property type="chains" value="A=564-958"/>
</dbReference>
<dbReference type="PDB" id="4XUF">
<property type="method" value="X-ray"/>
<property type="resolution" value="3.20"/>
<property type="chains" value="A/B=600-947"/>
</dbReference>
<dbReference type="PDBsum" id="1RJB"/>
<dbReference type="PDBsum" id="3QS7"/>
<dbReference type="PDBsum" id="3QS9"/>
<dbReference type="PDBsum" id="4RT7"/>
<dbReference type="PDBsum" id="4XUF"/>
<dbReference type="ProteinModelPortal" id="P36888"/>
<dbReference type="SMR" id="P36888"/>
<dbReference type="BioGrid" id="108610">
<property type="interactions" value="13"/>
</dbReference>
<dbReference type="DIP" id="DIP-59769N"/>
<dbReference type="IntAct" id="P36888">
<property type="interactions" value="6"/>
</dbReference>
<dbReference type="MINT" id="MINT-7103562"/>
<dbReference type="STRING" id="9606.ENSP00000241453"/>
<dbReference type="BindingDB" id="P36888"/>
<dbReference type="ChEMBL" id="CHEMBL1974"/>
<dbReference type="DrugBank" id="DB06080">
<property type="generic name" value="ABT-869"/>
</dbReference>
<dbReference type="DrugBank" id="DB05213">
<property type="generic name" value="AC220"/>
</dbReference>
<dbReference type="DrugBank" id="DB05465">
<property type="generic name" value="MLN-518"/>
</dbReference>
<dbReference type="DrugBank" id="DB05216">
<property type="generic name" value="MP470"/>
</dbReference>
<dbReference type="DrugBank" id="DB09079">
<property type="generic name" value="Nintedanib"/>
</dbReference>
<dbReference type="DrugBank" id="DB08901">
<property type="generic name" value="Ponatinib"/>
</dbReference>
<dbReference type="DrugBank" id="DB00398">
<property type="generic name" value="Sorafenib"/>
</dbReference>
<dbReference type="DrugBank" id="DB01268">
<property type="generic name" value="Sunitinib"/>
</dbReference>
<dbReference type="DrugBank" id="DB05014">
<property type="generic name" value="XL999"/>
</dbReference>
<dbReference type="GuidetoPHARMACOLOGY" id="1807"/>
<dbReference type="iPTMnet" id="P36888"/>
<dbReference type="PhosphoSitePlus" id="P36888"/>
<dbReference type="BioMuta" id="FLT3"/>
<dbReference type="DMDM" id="156630887"/>
<dbReference type="MaxQB" id="P36888"/>
<dbReference type="PaxDb" id="P36888"/>
<dbReference type="PeptideAtlas" id="P36888"/>
<dbReference type="PRIDE" id="P36888"/>
<dbReference type="Ensembl" id="ENST00000241453">
<molecule id="P36888-1"/>
<property type="protein sequence ID" value="ENSP00000241453"/>
<property type="gene ID" value="ENSG00000122025"/>
</dbReference>
<dbReference type="GeneID" id="2322"/>
<dbReference type="KEGG" id="hsa:2322"/>
<dbReference type="UCSC" id="uc001urw.3">
<molecule id="P36888-1"/>
<property type="organism name" value="human"/>
</dbReference>
<dbReference type="CTD" id="2322"/>
<dbReference type="DisGeNET" id="2322"/>
<dbReference type="EuPathDB" id="HostDB:ENSG00000122025.14"/>
<dbReference type="GeneCards" id="FLT3"/>
<dbReference type="H-InvDB" id="HIX0037338"/>
<dbReference type="HGNC" id="HGNC:3765">
<property type="gene designation" value="FLT3"/>
</dbReference>
<dbReference type="HPA" id="HPA047539"/>
<dbReference type="MalaCards" id="FLT3"/>
<dbReference type="MIM" id="136351">
<property type="type" value="gene"/>
</dbReference>
<dbReference type="MIM" id="601626">
<property type="type" value="phenotype"/>
</dbReference>
<dbReference type="neXtProt" id="NX_P36888"/>
<dbReference type="OpenTargets" id="ENSG00000122025"/>
<dbReference type="Orphanet" id="98829">
<property type="disease" value="'Acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)'"/>
</dbReference>
<dbReference type="Orphanet" id="102724">
<property type="disease" value="'Acute myeloid leukemia with t(8;21)(q22;q22) translocation'"/>
</dbReference>
<dbReference type="Orphanet" id="98837">
<property type="disease" value="Acute biphenotypic leukemia"/>
</dbReference>
<dbReference type="Orphanet" id="98834">
<property type="disease" value="Acute myeloblastic leukemia with maturation"/>
</dbReference>
<dbReference type="Orphanet" id="98833">
<property type="disease" value="Acute myeloblastic leukemia without maturation"/>
</dbReference>
<dbReference type="Orphanet" id="98832">
<property type="disease" value="Minimally differentiated acute myeloblastic leukemia"/>
</dbReference>
<dbReference type="Orphanet" id="99860">
<property type="disease" value="Precursor B-cell acute lymphoblastic leukemia"/>
</dbReference>
<dbReference type="Orphanet" id="99861">
<property type="disease" value="Precursor T-cell acute lymphoblastic leukemia"/>
</dbReference>
<dbReference type="PharmGKB" id="PA28181"/>
<dbReference type="eggNOG" id="KOG0200">
<property type="taxonomic scope" value="Eukaryota"/>
</dbReference>
<dbReference type="eggNOG" id="COG0515">
<property type="taxonomic scope" value="LUCA"/>
</dbReference>
<dbReference type="GeneTree" id="ENSGT00760000118923"/>
<dbReference type="HOVERGEN" id="HBG005735"/>
<dbReference type="InParanoid" id="P36888"/>
<dbReference type="KO" id="K05092"/>
<dbReference type="OMA" id="FHRTWTE"/>
<dbReference type="OrthoDB" id="EOG091G01TL"/>
<dbReference type="PhylomeDB" id="P36888"/>
<dbReference type="TreeFam" id="TF325768"/>
<dbReference type="BRENDA" id="2.7.10.1">
<property type="organism ID" value="2681"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-449836">
<property type="pathway name" value="Other interleukin signaling"/>
</dbReference>
<dbReference type="SignaLink" id="P36888"/>
<dbReference type="SIGNOR" id="P36888"/>
<dbReference type="EvolutionaryTrace" id="P36888"/>
<dbReference type="GeneWiki" id="CD135"/>
<dbReference type="GenomeRNAi" id="2322"/>
<dbReference type="PRO" id="PR:P36888"/>
<dbReference type="Proteomes" id="UP000005640">
<property type="component" value="Chromosome 13"/>
</dbReference>
<dbReference type="Bgee" id="ENSG00000122025"/>
<dbReference type="CleanEx" id="HS_FLT3"/>
<dbReference type="ExpressionAtlas" id="P36888">
<property type="expression patterns" value="baseline and differential"/>
</dbReference>
<dbReference type="Genevisible" id="P36888">
<property type="organism ID" value="HS"/>
</dbReference>
<dbReference type="GO" id="GO:0005829">
<property type="term" value="C:cytosol"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0005783">
<property type="term" value="C:endoplasmic reticulum"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="HPA"/>
</dbReference>
<dbReference type="GO" id="GO:0005788">
<property type="term" value="C:endoplasmic reticulum lumen"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="UniProtKB-SubCell"/>
</dbReference>
<dbReference type="GO" id="GO:0005887">
<property type="term" value="C:integral component of plasma membrane"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="ProtInc"/>
</dbReference>
<dbReference type="GO" id="GO:0005634">
<property type="term" value="C:nucleus"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0005886">
<property type="term" value="C:plasma membrane"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="Reactome"/>
</dbReference>
<dbReference type="GO" id="GO:0043234">
<property type="term" value="C:protein complex"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0005524">
<property type="term" value="F:ATP binding"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="UniProtKB-KW"/>
</dbReference>
<dbReference type="GO" id="GO:0004896">
<property type="term" value="F:cytokine receptor activity"/>
<property type="evidence" value="ECO:0000250"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0035259">
<property type="term" value="F:glucocorticoid receptor binding"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0032403">
<property type="term" value="F:protein complex binding"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0042803">
<property type="term" value="F:protein homodimerization activity"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0043621">
<property type="term" value="F:protein self-association"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="CAFA"/>
</dbReference>
<dbReference type="GO" id="GO:0004714">
<property type="term" value="F:transmembrane receptor protein tyrosine kinase activity"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0005021">
<property type="term" value="F:vascular endothelial growth factor-activated receptor activity"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="ProtInc"/>
</dbReference>
<dbReference type="GO" id="GO:0031100">
<property type="term" value="P:animal organ regeneration"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0030183">
<property type="term" value="P:B cell differentiation"/>
<property type="evidence" value="ECO:0000250"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0071345">
<property type="term" value="P:cellular response to cytokine stimulus"/>
<property type="evidence" value="ECO:0000250"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0071385">
<property type="term" value="P:cellular response to glucocorticoid stimulus"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0035726">
<property type="term" value="P:common myeloid progenitor cell proliferation"/>
<property type="evidence" value="ECO:0000250"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0019221">
<property type="term" value="P:cytokine-mediated signaling pathway"/>
<property type="evidence" value="ECO:0000250"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0097028">
<property type="term" value="P:dendritic cell differentiation"/>
<property type="evidence" value="ECO:0000250"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0030097">
<property type="term" value="P:hemopoiesis"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="MGI"/>
</dbReference>
<dbReference type="GO" id="GO:0001776">
<property type="term" value="P:leukocyte homeostasis"/>
<property type="evidence" value="ECO:0000250"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0046651">
<property type="term" value="P:lymphocyte proliferation"/>
<property type="evidence" value="ECO:0000250"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0002318">
<property type="term" value="P:myeloid progenitor cell differentiation"/>
<property type="evidence" value="ECO:0000250"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0018108">
<property type="term" value="P:peptidyl-tyrosine phosphorylation"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0008284">
<property type="term" value="P:positive regulation of cell proliferation"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0043406">
<property type="term" value="P:positive regulation of MAP kinase activity"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0043410">
<property type="term" value="P:positive regulation of MAPK cascade"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0043552">
<property type="term" value="P:positive regulation of phosphatidylinositol 3-kinase activity"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0014068">
<property type="term" value="P:positive regulation of phosphatidylinositol 3-kinase signaling"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0042531">
<property type="term" value="P:positive regulation of tyrosine phosphorylation of STAT protein"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0002328">
<property type="term" value="P:pro-B cell differentiation"/>
<property type="evidence" value="ECO:0000250"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0046777">
<property type="term" value="P:protein autophosphorylation"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0042981">
<property type="term" value="P:regulation of apoptotic process"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0010243">
<property type="term" value="P:response to organonitrogen compound"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0007169">
<property type="term" value="P:transmembrane receptor protein tyrosine kinase signaling pathway"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="ProtInc"/>
</dbReference>
<dbReference type="Gene3D" id="2.60.40.10">
<property type="match status" value="4"/>
</dbReference>
<dbReference type="InterPro" id="IPR030118">
<property type="entry name" value="FLT3"/>
</dbReference>
<dbReference type="InterPro" id="IPR007110">
<property type="entry name" value="Ig-like_dom"/>
</dbReference>
<dbReference type="InterPro" id="IPR036179">
<property type="entry name" value="Ig-like_dom_sf"/>
</dbReference>
<dbReference type="InterPro" id="IPR013783">
<property type="entry name" value="Ig-like_fold"/>
</dbReference>
<dbReference type="InterPro" id="IPR013151">
<property type="entry name" value="Immunoglobulin"/>
</dbReference>
<dbReference type="InterPro" id="IPR011009">
<property type="entry name" value="Kinase-like_dom_sf"/>
</dbReference>
<dbReference type="InterPro" id="IPR000719">
<property type="entry name" value="Prot_kinase_dom"/>
</dbReference>
<dbReference type="InterPro" id="IPR017441">
<property type="entry name" value="Protein_kinase_ATP_BS"/>
</dbReference>
<dbReference type="InterPro" id="IPR001245">
<property type="entry name" value="Ser-Thr/Tyr_kinase_cat_dom"/>
</dbReference>
<dbReference type="InterPro" id="IPR008266">
<property type="entry name" value="Tyr_kinase_AS"/>
</dbReference>
<dbReference type="InterPro" id="IPR020635">
<property type="entry name" value="Tyr_kinase_cat_dom"/>
</dbReference>
<dbReference type="InterPro" id="IPR001824">
<property type="entry name" value="Tyr_kinase_rcpt_3_CS"/>
</dbReference>
<dbReference type="PANTHER" id="PTHR24416:SF356">
<property type="entry name" value="PTHR24416:SF356"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="Pfam" id="PF00047">
<property type="entry name" value="ig"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="Pfam" id="PF07714">
<property type="entry name" value="Pkinase_Tyr"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="SMART" id="SM00219">
<property type="entry name" value="TyrKc"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="SUPFAM" id="SSF48726">
<property type="entry name" value="SSF48726"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="SUPFAM" id="SSF56112">
<property type="entry name" value="SSF56112"/>
<property type="match status" value="2"/>
</dbReference>
<dbReference type="PROSITE" id="PS50835">
<property type="entry name" value="IG_LIKE"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="PROSITE" id="PS00107">
<property type="entry name" value="PROTEIN_KINASE_ATP"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="PROSITE" id="PS50011">
<property type="entry name" value="PROTEIN_KINASE_DOM"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="PROSITE" id="PS00109">
<property type="entry name" value="PROTEIN_KINASE_TYR"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="PROSITE" id="PS00240">
<property type="entry name" value="RECEPTOR_TYR_KIN_III"/>
<property type="match status" value="1"/>
</dbReference>
<proteinExistence type="evidence at protein level"/>
<keyword id="KW-0002">3D-structure</keyword>
<keyword id="KW-0025">Alternative splicing</keyword>
<keyword id="KW-0067">ATP-binding</keyword>
<keyword id="KW-0181">Complete proteome</keyword>
<keyword id="KW-0225">Disease mutation</keyword>
<keyword id="KW-1015">Disulfide bond</keyword>
<keyword id="KW-0256">Endoplasmic reticulum</keyword>
<keyword id="KW-0325">Glycoprotein</keyword>
<keyword id="KW-0393">Immunoglobulin domain</keyword>
<keyword id="KW-0418">Kinase</keyword>
<keyword id="KW-0472">Membrane</keyword>
<keyword id="KW-0547">Nucleotide-binding</keyword>
<keyword id="KW-0597">Phosphoprotein</keyword>
<keyword id="KW-0621">Polymorphism</keyword>
<keyword id="KW-0656">Proto-oncogene</keyword>
<keyword id="KW-0675">Receptor</keyword>
<keyword id="KW-1185">Reference proteome</keyword>
<keyword id="KW-0732">Signal</keyword>
<keyword id="KW-0808">Transferase</keyword>
<keyword id="KW-0812">Transmembrane</keyword>
<keyword id="KW-1133">Transmembrane helix</keyword>
<keyword id="KW-0829">Tyrosine-protein kinase</keyword>
<keyword id="KW-0832">Ubl conjugation</keyword>
<feature type="signal peptide" evidence="4">
<location>
<begin position="1"/>
<end position="26"/>
</location>
</feature>
<feature type="chain" description="Receptor-type tyrosine-protein kinase FLT3" id="PRO_0000016778">
<location>
<begin position="27"/>
<end position="993"/>
</location>
</feature>
<feature type="topological domain" description="Extracellular" evidence="4">
<location>
<begin position="27"/>
<end position="543"/>
</location>
</feature>
<feature type="transmembrane region" description="Helical" evidence="4">
<location>
<begin position="544"/>
<end position="563"/>
</location>
</feature>
<feature type="topological domain" description="Cytoplasmic" evidence="4">
<location>
<begin position="564"/>
<end position="993"/>
</location>
</feature>
<feature type="domain" description="Ig-like C2-type">
<location>
<begin position="253"/>
<end position="343"/>
</location>
</feature>
<feature type="domain" description="Protein kinase" evidence="6">
<location>
<begin position="610"/>
<end position="943"/>
</location>
</feature>
<feature type="nucleotide phosphate-binding region" description="ATP" evidence="6">
<location>
<begin position="616"/>
<end position="624"/>
</location>
</feature>
<feature type="region of interest" description="Important for normal regulation of the kinase activity and for maintaining the kinase in an inactive state in the absence of bound ligand">
<location>
<begin position="591"/>
<end position="597"/>
</location>
</feature>
<feature type="active site" description="Proton acceptor" evidence="6 7">
<location>
<position position="811"/>
</location>
</feature>
<feature type="binding site" description="ATP" evidence="37">
<location>
<position position="644"/>
</location>
</feature>
<feature type="modified residue" description="Phosphotyrosine" evidence="18 27">
<location>
<position position="572"/>
</location>
</feature>
<feature type="modified residue" description="Phosphoserine" evidence="18">
<location>
<position position="574"/>
</location>
</feature>
<feature type="modified residue" description="Phosphotyrosine; by autocatalysis" evidence="18 23 27">
<location>
<position position="589"/>
</location>
</feature>
<feature type="modified residue" description="Phosphotyrosine; by autocatalysis" evidence="15 17 18 23 27">
<location>
<position position="591"/>
</location>
</feature>
<feature type="modified residue" description="Phosphotyrosine; by autocatalysis" evidence="18 23 27">
<location>
<position position="599"/>
</location>
</feature>
<feature type="modified residue" description="Phosphotyrosine; by autocatalysis" evidence="17 23">
<location>
<position position="726"/>
</location>
</feature>
<feature type="modified residue" description="Phosphoserine" evidence="2">
<location>
<position position="759"/>
</location>
</feature>
<feature type="modified residue" description="Phosphotyrosine" evidence="23 27">
<location>
<position position="768"/>
</location>
</feature>
<feature type="modified residue" description="Phosphotyrosine" evidence="23 27">
<location>
<position position="793"/>
</location>
</feature>
<feature type="modified residue" description="Phosphotyrosine; by autocatalysis" evidence="17 23 27">
<location>
<position position="842"/>
</location>
</feature>
<feature type="modified residue" description="Phosphotyrosine; by autocatalysis" evidence="17 23 27">
<location>
<position position="955"/>
</location>
</feature>
<feature type="modified residue" description="Phosphotyrosine; by autocatalysis" evidence="17">
<location>
<position position="969"/>
</location>
</feature>
<feature type="modified residue" description="Phosphoserine" evidence="2">
<location>
<position position="993"/>
</location>
</feature>
<feature type="glycosylation site" description="N-linked (GlcNAc...) asparagine" evidence="28">
<location>
<position position="43"/>
</location>
</feature>
<feature type="glycosylation site" description="N-linked (GlcNAc...) asparagine" evidence="28">
<location>
<position position="100"/>
</location>
</feature>
<feature type="glycosylation site" description="N-linked (GlcNAc...) asparagine" evidence="28">
<location>
<position position="151"/>
</location>
</feature>
<feature type="glycosylation site" description="N-linked (GlcNAc...) asparagine" evidence="28">
<location>
<position position="306"/>
</location>
</feature>
<feature type="glycosylation site" description="N-linked (GlcNAc...) asparagine" evidence="28">
<location>
<position position="323"/>
</location>
</feature>
<feature type="glycosylation site" description="N-linked (GlcNAc...) asparagine" evidence="28">
<location>
<position position="351"/>
</location>
</feature>
<feature type="glycosylation site" description="N-linked (GlcNAc...) asparagine" evidence="28">
<location>
<position position="354"/>
</location>
</feature>
<feature type="glycosylation site" description="N-linked (GlcNAc...) asparagine">
<location>
<position position="473"/>
</location>
</feature>
<feature type="glycosylation site" description="N-linked (GlcNAc...) asparagine">
<location>
<position position="502"/>
</location>
</feature>
<feature type="glycosylation site" description="N-linked (GlcNAc...) asparagine" evidence="4">
<location>
<position position="541"/>
</location>
</feature>
<feature type="disulfide bond" evidence="5 28">
<location>
<begin position="35"/>
<end position="65"/>
</location>
</feature>
<feature type="disulfide bond" evidence="5 28">
<location>
<begin position="103"/>
<end position="114"/>
</location>
</feature>
<feature type="disulfide bond" evidence="5 28">
<location>
<begin position="199"/>
<end position="206"/>
</location>
</feature>
<feature type="disulfide bond" evidence="5 28">
<location>
<begin position="232"/>
<end position="241"/>
</location>
</feature>
<feature type="disulfide bond" evidence="5 28">
<location>
<begin position="272"/>
<end position="330"/>
</location>
</feature>
<feature type="disulfide bond" evidence="5 28">
<location>
<begin position="368"/>
<end position="407"/>
</location>
</feature>
<feature type="disulfide bond" evidence="5 28">
<location>
<begin position="381"/>
<end position="392"/>
</location>
</feature>
<feature type="splice variant" description="In isoform 2." id="VSP_041796" evidence="36">
<location>
<begin position="807"/>
<end position="847"/>
</location>
</feature>
<feature type="sequence variant" description="In dbSNP:rs12872889." id="VAR_034677">
<original>D</original>
<variation>G</variation>
<location>
<position position="7"/>
</location>
</feature>
<feature type="sequence variant" description="In dbSNP:rs56321896." id="VAR_042069" evidence="19">
<original>V</original>
<variation>A</variation>
<location>
<position position="158"/>
</location>
</feature>
<feature type="sequence variant" description="In dbSNP:rs146030737." id="VAR_054149" evidence="22">
<original>V</original>
<variation>M</variation>
<location>
<position position="194"/>
</location>
</feature>
<feature type="sequence variant" description="In dbSNP:rs1933437." id="VAR_034678" evidence="14 19 31 35">
<original>T</original>
<variation>M</variation>
<location>
<position position="227"/>
</location>
</feature>
<feature type="sequence variant" description="In dbSNP:rs35602083." id="VAR_042070" evidence="19">
<original>D</original>
<variation>N</variation>
<location>
<position position="324"/>
</location>
</feature>
<feature type="sequence variant" description="In dbSNP:rs34172843." id="VAR_042071" evidence="19">
<original>D</original>
<variation>V</variation>
<location>
<position position="358"/>
</location>
</feature>
<feature type="sequence variant" description="In dbSNP:rs56090538." id="VAR_061291">
<original>I</original>
<variation>L</variation>
<location>
<position position="417"/>
</location>
</feature>
<feature type="sequence variant" description="In dbSNP:rs35958982." id="VAR_042072" evidence="19">
<original>V</original>
<variation>I</variation>
<location>
<position position="557"/>
</location>
</feature>
<feature type="sequence variant" description="In acute lymphoblastic leukemia patients and acute myelogenous leukemia patients; somatic mutation; constitutively activated; dbSNP:rs121913487." id="VAR_065679" evidence="10 12">
<original>D</original>
<variation>E</variation>
<location>
<position position="835"/>
</location>
</feature>
<feature type="sequence variant" description="In acute lymphoblastic leukemia patients and in acute myelogenous leukemia patients; somatic mutation; constitutively activated; dbSNP:rs121913488." id="VAR_065680" evidence="10 11 12">
<original>D</original>
<variation>H</variation>
<location>
<position position="835"/>
</location>
</feature>
<feature type="sequence variant" description="In acute lymphoblastic leukemia patients and in acute myelogenous leukemia patients; somatic mutation; constitutively activated; dbSNP:rs121913488." id="VAR_065681" evidence="10">
<original>D</original>
<variation>N</variation>
<location>
<position position="835"/>
</location>
</feature>
<feature type="sequence variant" description="In acute lymphoblastic leukemia patients and in acute myelogenous leukemia patients; somatic mutation; constitutively activated; dbSNP:rs121909646." id="VAR_065682" evidence="10">
<original>D</original>
<variation>V</variation>
<location>
<position position="835"/>
</location>
</feature>
<feature type="sequence variant" description="In acute lymphoblastic leukemia patients and in acute myelogenous leukemia patients; somatic mutation; constitutively activated; dbSNP:rs121913488." id="VAR_065683" evidence="10 11 12">
<original>D</original>
<variation>Y</variation>
<location>
<position position="835"/>
</location>
</feature>
<feature type="sequence variant" description="In acute lymphoblastic leukemia patients; somatic mutation; dbSNP:rs121913232." id="VAR_065684" evidence="12">
<original>I</original>
<variation>M</variation>
<location>
<position position="836"/>
</location>
</feature>
<feature type="mutagenesis site" description="Reduced phosphorylation of the wild-type kinase in response to ligand binding. No effect on the phosphorylation of the constitutively activated mutant kinase variants. Abolishes activation of STAT5A." evidence="17 18 34">
<original>Y</original>
<variation>F</variation>
<location>
<position position="589"/>
</location>
</feature>
<feature type="mutagenesis site" description="No significant effect on tyrosine phosphorylation. Abolishes activation of STAT5A." evidence="17 34">
<original>Y</original>
<variation>F</variation>
<location>
<position position="591"/>
</location>
</feature>
<feature type="mutagenesis site" description="Abolishes interaction with PTPN11/SHP2 and phosphorylation of PTPN11/SHP2." evidence="18">
<original>Y</original>
<variation>F</variation>
<location>
<position position="599"/>
</location>
</feature>
<feature type="mutagenesis site" description="Abolishes kinase activity." evidence="15">
<original>K</original>
<variation>A</variation>
<location>
<position position="644"/>
</location>
</feature>
<feature type="sequence conflict" description="In Ref. 1; AAA18947." ref="1" evidence="37">
<original>G</original>
<variation>A</variation>
<location>
<position position="8"/>
</location>
</feature>
<feature type="sequence conflict" description="In Ref. 1; AAA18947." ref="1" evidence="37">
<original>QL</original>
<variation>TV</variation>
<location>
<begin position="10"/>
<end position="11"/>
</location>
</feature>
<feature type="sequence conflict" description="In Ref. 5; AAI44040." ref="5" evidence="37">
<original>S</original>
<variation>N</variation>
<location>
<position position="71"/>
</location>
</feature>
<feature type="sequence conflict" description="In Ref. 2; CAA81393." ref="2" evidence="37">
<original>A</original>
<variation>R</variation>
<location>
<position position="78"/>
</location>
</feature>
<feature type="sequence conflict" description="In Ref. 1; AAA18947." ref="1" evidence="37">
<original>E</original>
<variation>G</variation>
<location>
<position position="346"/>
</location>
</feature>
<feature type="sequence conflict" description="In Ref. 6; AAA35487." ref="6" evidence="37">
<original>T</original>
<variation>H</variation>
<location>
<position position="940"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="575"/>
<end position="581"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="583"/>
<end position="585"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="589"/>
<end position="591"/>
</location>
</feature>
<feature type="helix" evidence="1">
<location>
<begin position="594"/>
<end position="596"/>
</location>
</feature>
<feature type="helix" evidence="1">
<location>
<begin position="601"/>
<end position="603"/>
</location>
</feature>
<feature type="helix" evidence="1">
<location>
<begin position="607"/>
<end position="609"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="610"/>
<end position="618"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="620"/>
<end position="631"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="633"/>
<end position="636"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="638"/>
<end position="646"/>
</location>
</feature>
<feature type="helix" evidence="1">
<location>
<begin position="656"/>
<end position="668"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="677"/>
<end position="681"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="683"/>
<end position="686"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="688"/>
<end position="692"/>
</location>
</feature>
<feature type="helix" evidence="1">
<location>
<begin position="699"/>
<end position="704"/>
</location>
</feature>
<feature type="turn" evidence="1">
<location>
<begin position="705"/>
<end position="708"/>
</location>
</feature>
<feature type="helix" evidence="1">
<location>
<begin position="785"/>
<end position="804"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="807"/>
<end position="809"/>
</location>
</feature>
<feature type="helix" evidence="1">
<location>
<begin position="814"/>
<end position="816"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="817"/>
<end position="820"/>
</location>
</feature>
<feature type="turn" evidence="1">
<location>
<begin position="821"/>
<end position="823"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="824"/>
<end position="827"/>
</location>
</feature>
<feature type="helix" evidence="1">
<location>
<begin position="831"/>
<end position="833"/>
</location>
</feature>
<feature type="helix" evidence="1">
<location>
<begin position="836"/>
<end position="838"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="842"/>
<end position="845"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="848"/>
<end position="850"/>
</location>
</feature>
<feature type="helix" evidence="1">
<location>
<begin position="852"/>
<end position="854"/>
</location>
</feature>
<feature type="helix" evidence="1">
<location>
<begin position="857"/>
<end position="862"/>
</location>
</feature>
<feature type="helix" evidence="1">
<location>
<begin position="867"/>
<end position="881"/>
</location>
</feature>
<feature type="turn" evidence="1">
<location>
<begin position="882"/>
<end position="884"/>
</location>
</feature>
<feature type="helix" evidence="1">
<location>
<begin position="896"/>
<end position="903"/>
</location>
</feature>
<feature type="helix" evidence="1">
<location>
<begin position="916"/>
<end position="925"/>
</location>
</feature>
<feature type="helix" evidence="1">
<location>
<begin position="930"/>
<end position="932"/>
</location>
</feature>
<feature type="helix" evidence="1">
<location>
<begin position="936"/>
<end position="946"/>
</location>
</feature>
<evidence key="1" type="ECO:0000244">
<source>
<dbReference type="PDB" id="1RJB"/>
</source>
</evidence>
<evidence key="2" type="ECO:0000244">
<source>
<dbReference type="PubMed" id="19369195"/>
</source>
</evidence>
<evidence key="3" type="ECO:0000250">
<source>
<dbReference type="UniProtKB" id="Q00342"/>
</source>
</evidence>
<evidence key="4" type="ECO:0000255"/>
<evidence key="5" type="ECO:0000255">
<source>
<dbReference type="PROSITE-ProRule" id="PRU00114"/>
</source>
</evidence>
<evidence key="6" type="ECO:0000255">
<source>
<dbReference type="PROSITE-ProRule" id="PRU00159"/>
</source>
</evidence>
<evidence key="7" type="ECO:0000255">
<source>
<dbReference type="PROSITE-ProRule" id="PRU10028"/>
</source>
</evidence>
<evidence key="8" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="10080542"/>
</source>
</evidence>
<evidence key="9" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="11090077"/>
</source>
</evidence>
<evidence key="10" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="11290608"/>
</source>
</evidence>
<evidence key="11" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="11442493"/>
</source>
</evidence>
<evidence key="12" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="14504097"/>
</source>
</evidence>
<evidence key="13" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="14759363"/>
</source>
</evidence>
<evidence key="14" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="15489334"/>
</source>
</evidence>
<evidence key="15" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="15831474"/>
</source>
</evidence>
<evidence key="16" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="16266983"/>
</source>
</evidence>
<evidence key="17" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="16627759"/>
</source>
</evidence>
<evidence key="18" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="16684964"/>
</source>
</evidence>
<evidence key="19" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="17344846"/>
</source>
</evidence>
<evidence key="20" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="18305215"/>
</source>
</evidence>
<evidence key="21" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="18490735"/>
</source>
</evidence>
<evidence key="22" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="18987736"/>
</source>
</evidence>
<evidence key="23" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="19477218"/>
</source>
</evidence>
<evidence key="24" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="20111072"/>
</source>
</evidence>
<evidence key="25" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="20508617"/>
</source>
</evidence>
<evidence key="26" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="21067588"/>
</source>
</evidence>
<evidence key="27" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="21262971"/>
</source>
</evidence>
<evidence key="28" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="21389326"/>
</source>
</evidence>
<evidence key="29" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="21516120"/>
</source>
</evidence>
<evidence key="30" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="7507245"/>
</source>
</evidence>
<evidence key="31" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="8394751"/>
</source>
</evidence>
<evidence key="32" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="8637232"/>
</source>
</evidence>
<evidence key="33" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="8946930"/>
</source>
</evidence>
<evidence key="34" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="9737679"/>
</source>
</evidence>
<evidence key="35" type="ECO:0000269">
<source ref="4"/>
</evidence>
<evidence key="36" type="ECO:0000303">
<source>
<dbReference type="PubMed" id="15489334"/>
</source>
</evidence>
<evidence key="37" type="ECO:0000305"/>
<sequence length="993" mass="112903" checksum="6C1995718F352ECE" modified="2007-08-21" version="2" precursor="true">
MPALARDGGQLPLLVVFSAMIFGTITNQDLPVIKCVLINHKNNDSSVGKSSSYPMVSESP
EDLGCALRPQSSGTVYEAAAVEVDVSASITLQVLVDAPGNISCLWVFKHSSLNCQPHFDL
QNRGVVSMVILKMTETQAGEYLLFIQSEATNYTILFTVSIRNTLLYTLRRPYFRKMENQD
ALVCISESVPEPIVEWVLCDSQGESCKEESPAVVKKEEKVLHELFGTDIRCCARNELGRE
CTRLFTIDLNQTPQTTLPQLFLKVGEPLWIRCKAVHVNHGFGLTWELENKALEEGNYFEM
STYSTNRTMIRILFAFVSSVARNDTGYYTCSSSKHPSQSALVTIVEKGFINATNSSEDYE
IDQYEEFCFSVRFKAYPQIRCTWTFSRKSFPCEQKGLDNGYSISKFCNHKHQPGEYIFHA
ENDDAQFTKMFTLNIRRKPQVLAEASASQASCFSDGYPLPSWTWKKCSDKSPNCTEEITE
GVWNRKANRKVFGQWVSSSTLNMSEAIKGFLVKCCAYNSLGTSCETILLNSPGPFPFIQD
NISFYATIGVCLLFIVVLTLLICHKYKKQFRYESQLQMVQVTGSSDNEYFYVDFREYEYD
LKWEFPRENLEFGKVLGSGAFGKVMNATAYGISKTGVSIQVAVKMLKEKADSSEREALMS
ELKMMTQLGSHENIVNLLGACTLSGPIYLIFEYCCYGDLLNYLRSKREKFHRTWTEIFKE
HNFSFYPTFQSHPNSSMPGSREVQIHPDSDQISGLHGNSFHSEDEIEYENQKRLEEEEDL
NVLTFEDLLCFAYQVAKGMEFLEFKSCVHRDLAARNVLVTHGKVVKICDFGLARDIMSDS
NYVVRGNARLPVKWMAPESLFEGIYTIKSDVWSYGILLWEIFSLGVNPYPGIPVDANFYK
LIQNGFKMDQPFYATEEIYIIMQSCWAFDSRKRPSFPNLTSFLGCQLADAEEAMYQNVDG
RVSECPHTYQNRRPFSREMDLGLLSPQAQVEDS
</sequence>
</entry>
<copyright>
Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
Distributed under the Creative Commons Attribution-NoDerivs License
</copyright>
</uniprot>